Empowered Funds
SRPT icon

Empowered Funds’s Sarepta Therapeutics SRPT Stock Holding History

Empowered Funds’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,235
Closed -$3.01M – 694
2022
Q4 		$3.01M Buy
+23,235
New +$2.69M 0.2% 150

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Empowered Funds's SRPT Position: Q2 2026 in Review

Empowered Funds increased its Sarepta Therapeutics (SRPT) stake by 67% in Q2 2026, buying an estimated $1.45M and bringing the position to 190,586 shares worth $3.42M. The position accounts for 0.02% of the portfolio, ranked #892.

Empowered Funds first reported a position in SRPT in Q1 2018 and has held it in 6 quarters since. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Empowered Funds held 190,586 shares of Sarepta Therapeutics worth $3.42M as of Q2 2026.
  • Empowered Funds bought 76,651 Sarepta Therapeutics shares in Q2 2026, an estimated $1.45M.
  • Sarepta Therapeutics made up 0.02% of Empowered Funds's portfolio in Q2 2026, its #892 holding.
  • Empowered Funds first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 6 quarters since.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.